Clinical Trials Directory

Trials / Sponsors / Shanghai Miracogen Inc.

Shanghai Miracogen Inc.

Industry · 23 registered clinical trials4 currently recruiting.

StatusTrialPhaseStarted
Not Yet RecruitingA Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment o
Advanced Pancreatic Cancer
Phase 32026-01-01
RecruitingA Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recur
Recurrent or Metastatic Nasopharyngeal Carcinoma
Phase 32025-05-06
Active Not RecruitingA Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Car
Recurrent or Metastatic Nasopharyngeal Carcinoma
Phase 22023-04-06
RecruitingA Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive
Advanced or Metastatic Urothelium Cancer
Phase 32023-04-06
UnknownA Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN
Squamous Cell Carcinoma of the Head and Neck
Phase 32023-03-01
UnknownA Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.
Advanced Malignant Solid Tumors
Phase 1 / Phase 22022-08-05
UnknownA Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors
Advanced Solid Tumors
Phase 1 / Phase 22022-06-30
UnknownA Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients
Breast Cancer With Liver Metastases
Phase 22022-03-23
UnknownA Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesop
Locally Advanced Gastric Cancer, Metastatic HER2 Positive Gastroesophageal Junction Cancer
Phase 22022-01-19
UnknownA Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung C
Non-small- Cell Lung Cancer (NSCLC)
Phase 22021-12-01
UnknownA Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors
Advanced or Metastatic Solid Tumors
Phase 1 / Phase 22021-07-26
UnknownA Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic
Advanced Breast Cancer, Metastatic Breast Cancer
Phase 2 / Phase 32021-06-30
UnknownA Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract
Advanced or Metastatic Biliary Tract Cancer
Phase 22021-06-07
UnknownA Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.
Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Gastroesophageal Junction Carcinoma
Phase 22021-05-24
Active Not RecruitingA Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gast
Advanced Solid Tumors, Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Gastroesophageal Junction Cancer
Phase 1 / Phase 22021-05-24
UnknownA Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)
Advanced or Metastatic Breast Cancer
Phase 22021-05-13
UnknownA Study of MRG003 in the Treatment of EGFR-positive Unresectable, Locally Advanced or Metastatic Biliary Tract
Advanced or Metastatic Biliary Tract Cancer
Phase 22021-04-28
RecruitingA Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell C
Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
Phase 22021-04-23
UnknownA Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Can
Locally Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma
Phase 22021-04-20
UnknownA Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell L
Carcinoma, Non-Small-Cell Lung
Phase 22020-09-04
UnknownSafety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL)
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)
Phase 12019-06-25
UnknownA Study of MRG002 in the Treatment of Patients With HER2-positive Advanced Solid Tumors
Advanced Solid Tumor
Phase 12018-11-21
CompletedA Study of MRG003 in Patients With Advanced Solid Tumors
Advanced Solid Tumors
Phase 12018-05-09